A unique partnership between industry and academia has led to human clinical trials of a new drug for a rare class of blood diseases called myeloproliferative disorders (MPD), which are all driven by the same genetic mutation and can evolve into leukemia.

While doctors already face many challenges in treating patients with cancer, treating pregnant women with the disease, in particular, can be quite difficult as studies suggest that certain therapies can harm developing fetuses.

A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.

Adult stem cell therapy has successfully treated leukemia and other cancers for years, in the form of bone marrow transplants.

A rare disorder caused by an excess of two types of immune cells—the mast cell found in various tissues and its blood-based twin, the basophil—has successfully been treated with a cancer drug, report scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

A research team at the Moores Cancer Center at University of California, San Diego (UCSD) reports that patients with chronic lymphocytic leukemia (CLL) who were treated with a gene therapy protocol began making antibodies that reacted against their own leukemia cells.

Researchers have identified a potential new mechanism through which human T-lymphotropic virus type-1 (HTLV-1) causes leukemia in adults. The findings, published this week in the online open access journal Retrovirology, represent the first time that a reduction in histone protein levels has been linked to viral infection and the development of cancer.

New research suggests that certain small molecules used by cells to control the proteins they make might also help doctors identify adult acute-leukemia patients who are likely to respond poorly to therapy.

A new scoring system for a form of leukemia known as myelodysplastic syndrome (MDS) identifies patients who appear to have low-risk disease but actually have poor prospects of survival, researchers at The University of Texas M. D. Anderson Cancer Center report online at the journal Leukemia.

Oregon Health & Science University Cancer Institute researcher Jeff Tyner, Ph.D., has created a way to identify proteins that are candidates for targeted therapy in acute myeloid leukemia using an assay that yields results in just four days.

Mayo Clinic researchers today reported the discovery of a link between erythropoiesis-stimulating agents (ESAs) and leukemic transformation (conversion to leukemia) of the blood disorder myelofibrosis.

Scientists here have found that mini-molecules called micro-RNA may play a critical role in the progression of chronic myeloid leukemia (CML) from its more treatable chronic phase to a life-threatening phase, called blast crisis.